비전이성 유방암 수술환자의 보조화학요법 현황

키워드

참고문헌 (31)

1. 박수경, "한국인에서 유방암의 역학적 특성", 대한의사협회지, 62(8), pp.424~436 (2019), 대한의사협회
2. Hammer C, "Overview of breast cancer staging and surgical treatment options", Cleve Clin J Med, 75, pp.S11~ (2008)
3. Moo T-A, "Overview of breast cancer therapy", PET clin, 13(3), pp.339~354 (2018)
4. Veronesi U, "Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer", N Engl J Med, 347(16), pp.1227~1232 (2002)
5. Fisher B, "Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer", N Engl J Med, 347(16), pp.1233~1241 (2002)
6. Poggi MM, "Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy", Cancer, 98(4), pp.697~702 (2003)
7. Voogd AC, "Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer : pooled results of two large european randomized trials", J Clin Oncol, 19(6), pp.1688~1697 (2001)
8. 김아영, "즉시 유방재건술을 받은 유방암 환자의 수술만족도와 삶의 질", Asian Oncology Nursing, 20(1), pp.1~9 (2020), 대한종양간호학회[DOI]
9. Lohrisch C, "Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer", J Clin Oncol, 24(3), pp.4888~4894 (2006)
10. Kupstas AR, "Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival : a national cancer database analysis", Ann Surg Oncol, 26(10), pp.3240~3249 (2019)
11. Bonadonna G, "Combination chemotherapy as an adjuvant treatment in operable breast cancer", N Engl J Med, 294(8), pp.405~410 (1976)
12. Jung YS, "Adjuvant chemotherapy in operable breast cancer", Korean J Clin Oncol, 4(2), pp.30~36 (2008)
13. Fisher B, "Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6months of cyclophosphamide, methotrexate, and fluorouracil in positivenode breast cancer patients with tamoxifen-nonresponsive tumors : results from the National Surgical Adjuvant Breast and Bowel Project B-15", J Clin Oncol, 8(9), pp.1483~1496 (1990)
14. Fisher B, "Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor–negative breast cancer : findings from national surgical adjuvant breast and bowel project B-23", J Clin Oncol, 19(4), pp.931~942 (2001)
15. Albain KA, "Comparisons between different polychemotherapy regimens for early breast cancer : meta-analyses of longterm outcome among 100, 000 women in 123 randomised trials", Lancet, 379(9814), pp.432~444 (2012)
16. Levine MN, "Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer", J Clin Oncol, 16(8), pp.2651~2658 (1998)
17. Coombes RC, "Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial", J Clin Oncol., 14(1), pp.35~45 (1996), The International Collaborative Cancer Group
18. Henderson IC, "Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer", J Clin Oncol, 21(6), pp.976~983 (2003)
19. Jones S, "Docetaxel with cyclophosphamide Is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of US Oncology Research Trial 9735", J Clin Oncol, 27(8), pp.1177~1183 (2009)
20. Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)
21. 김경훈, "Charlson 동반질환의 ICD-10 알고리즘 예측력 비교연구", 예방의학회지, 43(1), pp.42~49 (2010), 대한예방의학회
22. Akça M, "Impact of surgery type on quality of life in breast cancer patients", J Breast Health, 10(4), pp.222~ (2014)
23. "National Comprehensive Cancer Network (nccn) NCCN clinical practice guidelines in oncology: Breast Cancer", NCCN; 2018. Ver. 1, ~ (2018)
24. 건강보험심사평가원, "암환자에게 처방·투여하는약제에 대한 요양급여의 적용기준 및 방법에 관한 세부사항", 건강보험심사평가원, 63~72 (2018)
25. Jones SE, "Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for pperable breast cancer", J Clin Oncol, 24(34), pp.5381~5387 (2006)
26. Doyle JJ, "Chemotherapy and cardiotoxicity in older breast cancer patients : a population-based study", J Clin Oncol, 23(34), pp.8597~8605 (2005)
27. Markman M, "Managing taxane toxicities", Supportive Care Cancer, 11(3), pp.144~147 (2003)
28. Moja L, "Trastuzumab containing regimens for early breast cancer", Cochrane Database Syst Rev, 2012, pp.CD006243~CD (2012)
29. Seidman A, "Cardiac dysfunction in the trastuzumab clinical trials experience", J Clin Oncol, 20(5), pp.1215~1221 (2002)
30. Lin C-H, "Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population", JNCI : J Natl Cancer Inst, 111(12), pp.1298~1306 (2019)
31. 정일용, "Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data", Journal of Korean Medical Science, 33(44), pp.1~10 (2018), 대한의학회

관련 논문AI추천